Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 327

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 327
---
oes imposed, authorized, administered or enforced by any Governmental Entity of Canada, the United States, the UK, or the EU or its member states (collectively, “Sanctions”).                                     |

| (b) | Neither the Company nor its Subsidiary are organized, resident or located in any country or territory that is                                                                                                                                   
 the target of comprehensive Sanctions, including (as at the date hereof) Belarus, Central African Republic, China, Democratic People’s Republic of Korea (North Kora), Democratic Republic Of the Congo, Guatemala, Haiti, Iran, Iraq, Lebanon, 
 Libya, Moldova, Myanmar, Nicaragua, Russia, Somalia, South Sudan, Sri Lanka, Sudan, Syria, the occupied Crimea, Donetsk, Luhansk, Kherson and Zaporizhzhia regions of Ukraine, Venezuela, Yemen and Zimbabwe.                                   |

A-82

| 36. | Consents and Approvals |

| (a) | Other than as set out in Schedule 36 to the Disclosure Letter, there are no Regulatory Approvals required to be 
 obtained by the Company in order to complete the Contemplated Transactions and the Distribution.                |

| (b) | There is no requirement under applicable Securities Laws for the Company to make any filing, give any notice or                                                                                                                                     
 obtain any permit as a condition to the lawful consummation of the transactions contemplated by this Agreement or otherwise obtain any governmental approvals, other than (i) the filing with the SEC of such reports under the US Exchange Act as  
 may be required in connection with the Agreement and the Contemplated Transactions and (ii) filings required to be made following the Effective Time under applicable Securities Laws. Except for such notices as have been given and such consents 
 as have been obtained, there is no requirement under any Material Contract to give any notice to, or to obtain the consent or approval of, any Party to such Material Contract, relating to, in connection with or as a result of the execution and 
 delivery of this Agreement or the consummation of the transactions contemplated this Agreement.                                                                                                                                                     |

| 37. | Intellectual Property Matters |

| (a) | To the knowledge of the Company, neither the Company nor or its Subsidiary has received any written notice or                                                         
 claim challenging the Company or its Subsidiary with respect to the validity of, use of or ownership of the Intellectual Property used or owned by it, as applicable. |

| (b) | The operation or conduct of the business